Company intelligence / Profile preview

Neural Therapeutics Inc.

Toronto, Ontario, Canadaneuraltherapeutics.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

Neural Therapeutics is developing mescaline-based mental health treatments using sub-hallucinogenic doses for various DSM-5 disorders. The company has filed a patent application for treatment methods and novel extraction technology for producing pharma-grade products[3].

Therapeutic areas: Psychiatry
Modalities: Ethnobotanical compoundsMescaline extractsPlant-based active substances
Industry: Biotech

Drug pipeline

1 asset

mescaline

Pre-clinical

Indications: Substance use disorders, Alcohol dependence, Opioid dependence

Partnerships

CWE European Holdings Inc. (dba Hanf.com) - signed a non-binding letter of intent to acquire an interest[2][6]

Beyond the preview

Go deeper on Neural Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neural Therapeutics Inc..

Explore the full profile